phospholipase A2 group 7; platelet-activating factor acetylhydrolase; PAF acetylhydrolase; PAF 2-acylhydrolase; LDL-associated phospholipase A2; LDL-PLA2; lipoprotein-associated phospholipase A2; 2-acetyl-1-alkylglycerophosphocholine esterase; 1-alkyl-2-acetylglycerophosphocholine esterase (PAFAH, PLA2G7)
Jump to navigation
Jump to search
Function
- modulates the action of platelet-activating factor (PAF) by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF
- has a specificity for substrates with a short residue at the sn-2 position
- inactive against long-chain phospholipids
1-alkyl-2-acetyl-sn-glycero-3-phosphocholine + H2O = 1-alkyl-sn-glycero-3-phosphocholine + acetate
Structure
- belongs to the AB hydrolase superfamily, lipase family
Compartment
Expression
- the source of plasma PAF acetylhydrolase is not known, but cultured macrophages secrete large amounts & hepatocytes secrete less
Pathology
- defects in PLA2G7 are the cause of platelet-activating factor acetylhydrolase deficiency
- marker for vascular inflammation[4]
Polymorphism
Comparative biology
- there is apparently an intracellular enzyme of bovine brain that shares no sequence similarity outside the region of the active site
More general terms
Additional terms
References
- ↑ Tjoelker LW et al Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374:549 1995 PMID: https://www.ncbi.nlm.nih.gov/pubmed/7700381
- ↑ UniProt http://www.uniprot.org/uniprot/Q13093.html
- ↑ SeattleSNPs http://pga.gs.washington.edu/data/pla2g7/
- ↑ 4.0 4.1 Young K, Fairchild DG, Di Francesco L FDA Clears Test to Help Predict Coronary Heart Disease Risk Physician's First Watch, Dec 17, 2014 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
FDA News Release. December 15, 2014 FDA clears test that helps predict the risk of coronary heart disease. Study data show test predicts risk better in black women. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426799.htm